ABO subgroup incompatibility with severe hemolysis after consecutive allogeneic stem cell transplantations

• DOI: 10.1002/jha2.190
• Publication Date: 2021-03-24T09:55:10Z
• Authors: Judith S. Hecker; Adam Wahida; Erik Hameister; Aneta Filo; Jürgen Ruland; Florian Bassermann; Martin Hildebrandt; Mareike Verbeek; Hendrik Poeck
• Keywords: 03 medical and health sciences; 0302 clinical medicine; A1/A2 subtyping of blood group A; Diseases of the blood and blood-forming organs; allogeneic hematopoietic stem cell transplantation; Case Reports; hemolysis; RC633-647.5; ABO incompatibility; 3. Good health

AbstractAllogeneic hematopoietic stem cell transplantations (HSCTs) represent a curative strategy for treating hematologic malignancies yet bear dangerous and frequently life‐threatening complications including the development of graft‐versus‐host disease. Here, we present a case of a patient that suffered from relapsed/refractory multiple myeloma, a hematologic neoplasm characterized by clonal proliferation of malignant plasma cells in the bone marrow. During the course of his disease, the patient underwent consecutive allogeneic HSCTs, during which he developed a clinical meaningful and hitherto unreported ABO subgroup incompatibility, leading to persistent hemolysis. Testing for ABO subgroups during donor selection, especially after consecutive allogeneic HSCTs, may therefore aid to prevent these complications.